Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review

Abstract

The pharmacokinetics of beta-lactam antibiotics in intensive care patients may be profoundly altered due to the dynamic, unpredictable pathophysiological changes that occur in critical illness. For many drugs, significant increases in the volume of distribution and/or variability in drug clearance are common. When "standard" beta-lactam doses are used, such pharmacokinetic changes can result in subtherapeutic plasma concentrations, treatment failure, and the development of antibiotic resistance. Emerging data support the use of beta-lactam therapeutic drug monitoring (TDM) and individualized dosing to ensure the achievement of pharmacodynamic targets associated with rapid bacterial killing and optimal clinical outcomes. The purpose of this work was to describe the pharmacokinetic variability of beta-lactams in the critically ill and to discuss the potential utility of TDM to optimize antibiotic therapy through a structured literature review of all relevant publications between 1946 and October 2011. Only a few studies have reported the utility of TDM as a tool to improve beta-lactam dosing in critically ill patients. Moreover, there is little agreement between studies on the pharmacodynamic targets required to optimize antibiotic therapy. The impact of TDM on important clinical outcomes also remains to be established. Whereas TDM may be theoretically rational, clinical studies to assess utility in the clinical setting are urgently required.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 118

1. 1.

   Roberts JA Norris R Paterson DL Martin JH Therapeutic drug monitoring of antimicrobialsBr J Clin Pharmacol2012 732736

   Not in our library10.1111/j.1365-2125.2011.04080.x

2. 2.

   van Lent-Evers NA Mathot RA Geus WP van Hout BA Vinks AA Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysisTher Drug Monit1999 216373

   Not in our library10.1097/00007691-199902000-00010

3. 3.

   Moise-Broder PA Forrest A Birmingham MC Schentag JJ Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infectionsClin Pharmacokinet2004 43925942

   Not in our library10.2165/00003088-200443130-00005

4. 4.

   Ariano RE Nyhlen A Donnelly JP Sitar DS Harding GK Zelenitsky SA Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremiaAnn Pharmacother2005 393238

   Not in our library10.1345/aph.1e271

5. 5.

   Li C Du X Kuti JL Nicolau DP Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infectionsAntimicrob Agents Chemother2007 5117251730

   Not in our library10.1128/aac.00294-06

6. 6.

   Lodise TP Lomaestro B Drusano GL Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategyClin Infect Dis2007 44357363

   Not in our library10.1086/510590

7. 7.

   McKinnon PS Paladino JA Schentag JJ Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infectionsInt J Antimicrob Ag2008 31345351

   Not in our library10.1016/j.ijantimicag.2007.12.009

8. 8.

   Niemiec PW Allo MD Miller CF Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive careArch Surg1987 122207212

   Not in our library10.1001/archsurg.1987.01400140089012

9. 9.

   Dorman T Swoboda S Zarfeshenfard F Trentler B Lipsett PA Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading doseCritical Care Research Group. Surgery1998 1247378

   Not in our library

10. 10.

    Roos JF Lipman J Kirkpatrick CM Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteriaIntensive Care Med2007 33781788

    Not in our library10.1007/s00134-007-0573-7

11. 11.

    Joukhadar C Frossard M Mayer BX Brunner M Klein N Siostrzonek P Eichler HG Muller M Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shockCrit Care Med2001 29385391

    Not in our library10.1097/00003246-200102000-00030

12. 12.

    Erlandsson M Burman LG Cars O Gill H Nilsson LE Walther SM Hanberger H Prescription of antibiotic agents in Swedish intensive care units is empiric and preciseScand J Infect Dis2007 396369

    Not in our library10.1080/00365540600740504

13. 13.

    Roberts JA Using PK/PD to optimize antibiotic dosing for critically ill patientsCurr Pharmaceut Biotechnol2011 1220702079

    Not in our library10.2174/138920111798808329

14. 14.

    Mohr JF Wanger A Rex JH Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patientsDiagn Micr Infec Dis2004 48125130

    Not in our library10.1016/j.diagmicrobio.2003.09.010

15. 15.
    Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams · 2011

    No notice
16. 16.

    Scaglione F Can PK/PD be used in everyday clinical practiceInt J Antimicrob Ag2002 19349353

    Not in our library10.1016/s0924-8579(02)00020-1

17. 17.

    Roberts JA Hope WW Lipman J Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential?Int J Antimicrob Agents2010 35419420

    Not in our library10.1016/j.ijantimicag.2010.01.022

18. 18.

    Lipman J Wallis SC Boots RJ Cefepime versus cefpirome: the importance of creatinine clearanceAnesth Analg2003 9711491154

    Not in our library10.1213/01.ane.0000077077.54084.b0

19. 19.

    Kieft H Hoepelman AI Knupp CA van Dijk A Branger JM Struyvenberg A Verhoef J Pharmacokinetics of cefepime in patients with the sepsis syndromeJ Antimicrob Chemother1993 32Suppl B117122

    Not in our library10.1093/jac/32.suppl_b.117

20. 20.
    Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock · 2010

    No notice
21. 21.

    Gomez CM Cordingly JJ Palazzo MG Altered pharmacokinetics of ceftazidime in critically ill patientsAntimicrob Agents Chemother1999 4317981802

    Not in our library10.1128/aac.43.7.1798

22. 22.

    Georges B Conil J-M Seguin T Ruiz S Minville V Cougot P Decun J-F Gonzalez H Houin G Fourcade O Saivin S Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admissionAntimicrob Agents Chemother2009 5344834489

    Not in our library10.1128/aac.00430-09

23. 23.

    Douglas A Udy AA Wallis SC Jarrett P Stuart J Lassig-Smith M Deans R Roberts MS Taraporewalla K Jenkins J Medley G Lipman J Roberts JA Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semi-elective abdominal aortic aneurysm open repair surgeryAntimicrob Agents Chemother2011 5552385242

    Not in our library10.1128/aac.05033-11

24. 24.

    Roberts JA Kirkpatrick CMJ Roberts MS Dalley AJ Lipman J First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsisInt J Antimicrob Ag2010 35156163

    Not in our library10.1016/j.ijantimicag.2009.10.008

25. 25.

    Garot D Respaud R Lanotte P Simon N Mercier E Ehrmann S Perrotin D Dequin PF Le Guellec C Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisalBr J Clin Pharmacol2011 72758767

    Not in our library10.1111/j.1365-2125.2011.04005.x

26. 26.

    Brink AJ Richards GA Schillack V Kiem S Schentag J Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsisInt J Antimicrob Ag2009 33432436

    Not in our library10.1016/j.ijantimicag.2008.10.005

27. 27.

    Ulldemolins M Roberts JA Wallis SC Rello J Lipman J Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokineticsJ Antimicrob Chemother2010 6517711778

    Not in our library10.1093/jac/dkq184

28. 28.

    Van Dalen R Vree TB Baars IM Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patientsPharm Weekbl Sci1987 998103

    Not in our library10.1007/bf01960743

29. 29.

    Moon YS Chung KC Gill MA Pharmacokinetics of meropenem in animals, healthy volunteers, and patientsClin Infect Dis1997 24Suppl 2S249S255

    Not in our library10.1093/clinids/24.supplement_2.s249

30. 30.

    Joynt GM Lipman J Gomersall CD Young RJ Wong EL Gin T The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patientsJ Antimicrob Chemother2001 47421429

    Not in our library10.1093/jac/47.4.421

31. 31.

    Udy AA Putt MT Shanmugathasan S Roberts JA Lipman J Augmented renal clearance in the Intensive Care Unit: an illustrative case seriesInt J Antimicrob Ag2010 35606608

    Not in our library10.1016/j.ijantimicag.2010.02.013

32. 32.

    Burkhardt O Kumar V Katterwe D Majcher-Peszynska J Drewelow B Derendorf H Welte T Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentrationJ Antimicrob Chemother2007 59277284

    Not in our library10.1093/jac/dkl485

33. 33.

    Lipman J Wallis SC Rickard C Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosingAntimicrob Agents Chemother1999 4325592561

    Not in our library10.1128/aac.43.10.2559

34. 34.

    Delattre IK Musuamba FT Verbeeck RK Dugernier T Spapen H Laterre P-F Wittebole X Cumps J Taccone FS Vincent J-L Jacobs F Wallemacq PE Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacinClin Biochem2010 43589598

    Not in our library10.1016/j.clinbiochem.2009.12.007

35. 35.

    Benko AS Cappelletty DM Kruse JA Rybak MJ Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infectionsAntimicrob Agents Chemother1996 40691695

    Not in our library10.1128/aac.40.3.691

36. 36.

    Young RJ Lipman J Gin T Gomersall CD Joynt GM Oh TE Intermittent bolus dosing of ceftazidime in critically ill patientsJ Antimicrob Chemother1997 40269273

    Not in our library10.1093/jac/40.2.269

37. 37.

    Thalhammer F Traunmuller F El Menyawi I Frass M Hollenstein UM Locker GJ Stoiser B Staudinger T Thalhammer-Scherrer R Burgmann H Continuous infusion versus intermittent administration of meropenem in critically ill patientsJ Antimicrob Chemother1999 43523527

    Not in our library10.1093/jac/43.4.523

38. 38.

    Novelli A Adembri C Livi P Fallani S Mazzei T De Gaudio AR Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsisClin Pharmacokinet2005 44539549

    Not in our library10.2165/00003088-200544050-00007

39. 39.

    Burkhardt O Derendorf H Welte T Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practiceExpert Opin Pharmacother2007 8237256

    Not in our library10.1517/14656566.8.2.237

40. 40.

    Boselli E Breilh D Saux M-C Gordien J-B Allaouchiche B Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumoniaIntens Care Med2006 3220592062

    Not in our library10.1007/s00134-006-0401-5

Cited by papers we hold 5

• The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance · 2021
  No notice
• Infection, Sepsis and the Inflammatory Response: Mechanisms and Therapy · 2020
  Not checked
• Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique—SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation—SFAR) · 2019
  No notice
• Meropenem pharmacokinetics in children: series of cases · 2018
  Not checked
• Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases · 2016
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.